New Recommendations Designed to Increase Early Diagnosis of HIV Infection as a Pathway to Improved Treatment and Prevention
StatSure Diagnostic Systems, Inc. – SSUR
The Center for Disease Control has determined routine testing is essential in the battle against HIV infection and AIDS, in America and globally.
The U.S. Centers for Disease Control and Prevention’s (CDC) HIV testing final recommendations were issued this week – that all Americans between the ages of 13 to 64 be tested for HIV as a part of routine medical care came just as the US Conference on AIDS began in Hollywood, Florida.
StatSure Diagnostic Systems, Inc. develops and manufactures rapid immunoassay tests for the detection of sexually transmitted and other infectious disease. The company also has developed and is marketing a product line of patented, oral-fluid collection devices.
The recommendation will expand the available market for StatSure’s barrel technology. Marketed under the name StatSure the barrel technology device is a self-contained, rapid whole-blood testing format for the detection of antibodies to a broad spectrum of infectious diseases. The sample is obtained though a small finger stick. Results can often be read within several minutes and do not require any instrumentation. This product line is designed for on-site testing in clinics, doctors’ offices, the military, mobile health vans, emergency situations, and those places where immediate results are necessary. All SDS rapid tests, StatSure and StatSimple, require no special handling, mixing, storage, electricity, refrigeration or specialized training (U.S. Patent #5,935,864).
The CDC recommendation will impact testing performed in hospitals and certified laboratories and will also impact public health clinics, doctors’ offices and other settings.
Stay tuned as Stock Guru examines the CDC recommendation and studies the SSUR impact.